Roche Holding (SWX:ROP) Reports Phase III Vamikibart Data In Uveitic Macular Edema

Genentech, part of Roche Holding (SWX:ROP), reported new Phase III results for vamikibart in uveitic macular edema (UME). The data suggest vamikibart could become the first non steroid targeted therapy option for this severe cause of vision loss. The FDA has accepted a Biologics License Application for vamikibart in UME, with a decision currently scheduled for 2027. These Phase III vamikibart results and the FDA filing only capture one side of Roche Holding's risk and opportunity mix. Our...